Dr. Ioana-Miruna Stanciu | Oncology | Best Researcher Award

Published on by Biotechnology Scientist

Dr. Ioana-Miruna Stanciu | Oncology | Best Researcher Award

Dr. Ioana-Miruna Stanciu | Carol Davila University of Medicine and Pharmacy | Romania

Dr. Ioana-Miruna Stanciu πŸŽ—οΈ is a dedicated medical oncologist and researcher based in Bucharest, Romania. She is an Assistant Lecturer at Carol Davila University of Medicine and Pharmacy and a Ph.D. candidate in Medical Oncology. With a passion for cancer treatment and translational research, she actively participates in clinical trials, supervises medical students, and presents at international oncology conferences. She is a member of prestigious oncology societies, including ESMO and ASCO. Her expertise spans immunotherapy, breast cancer, and precision medicine, contributing to advancements in oncology care and education. πŸ₯πŸ”¬πŸŽ€

Professional Profile:

ORCID

SCOPUS

Google Scholar

Suitability for Best Researcher Award

Dr. Ioana-Miruna Stanciu is a highly suitable candidate for the Best Researcher Award due to her significant contributions to oncology research, clinical trials, and education. As a Ph.D. candidate and Assistant Lecturer, she actively advances immunotherapy, breast cancer, and precision medicine. Her involvement in clinical trials, international oncology conferences, and prestigious societies like ESMO and ASCO highlights her global impact. Her dedication to translational research, patient care, and mentoring future oncologists makes her a deserving recipient of this recognition.

Education & Experience

  • πŸŽ“ Ph.D. in Medical Oncology – Carol Davila University of Medicine and Pharmacy, Bucharest (2021 – present)
  • πŸŽ“ Bachelor’s Degree in Medicine – Carol Davila University of Medicine and Pharmacy, Bucharest (2014 – 2020)
  • πŸŽ“ High School Degree – National College β€œMihai Viteazul,” Bucharest (2010 – 2014)
  • πŸ‘©β€πŸ« Assistant Lecturer in Medical Oncology – Carol Davila University of Medicine and Pharmacy, Bucharest (2022 – present)
  • 🏨 Resident in Medical Oncology – Elias University Emergency Hospital (2021 – present)
  • πŸ§‘β€πŸŽ“ Study Coordinator – AMGEN 20230016 Clinical Trial (2024)
  • πŸ“‘ Supervisor of 16 Bachelor’s Theses – September 2024 session

Professional Development

Dr. Ioana-Miruna Stanciu πŸ₯ has actively engaged in numerous oncology conferences, workshops, and research initiatives to enhance her expertise. She has attended global medical congresses such as ESMO, ASCO, and ROSPEN, presenting clinical cases and research findings on breast cancer, immunotherapy, and precision oncology. As a lecturer, she has contributed to oncology education, guiding students and professionals in advanced cancer treatments. Additionally, she plays a key role in clinical trials, helping to develop new therapeutic strategies. Through continuous learning and collaboration, she aims to improve cancer care and patient outcomes. πŸŽ€πŸ”¬πŸ“–

Research Focus

Dr. Stanciu’s research primarily focuses on medical oncology and immunotherapy, particularly in breast cancer, lung cancer, and systemic therapies. πŸŽ—οΈ She investigates the safety and efficacy of CDK4/6 inhibitors, advances in immune checkpoint inhibitors, and the management of adverse reactions in precision oncology. As a clinical trial coordinator, she contributes to groundbreaking studies in targeted therapies and immuno-oncology. πŸ”¬ Her expertise extends to translational oncology, aiming to bridge the gap between laboratory discoveries and real-world applications. By integrating clinical practice with research, she strives to improve patient survival and quality of life. πŸ₯πŸ©ΊπŸ“Š

Awards & Honors

πŸ† Invited Speaker – National and International Oncology Conferences 🎀
πŸ† Study Coordinator – AMGEN 20230016 Clinical Trial πŸ§ͺ
πŸ† Lecturer – Clinical Oncology Workshops & Summits πŸ“š
πŸ† Member – ESMO, ASCO, SNOMR, SRROM, and ROSPEN 🌍
πŸ† Scientific Contribution – Published research on precision medicine and immunotherapy πŸ”¬
πŸ† Supervisor – 16 Bachelor’s Theses on oncology-related topics πŸŽ“

Publication Top Notes:

πŸ“Œ The prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma – πŸ“ Current OncologyΒ πŸ”’ Cited by: 12
πŸ“Œ An overview of the safety profile and clinical impact of CDK4/6 inhibitors in breast cancerβ€”a systematic review of randomized phase II and III clinical trials – πŸ“ BiomoleculesΒ  πŸ”’ Cited by: 9
πŸ“Œ Metastatic kidney cancer: does the location of the metastases matter? Moving towards personalized therapy for metastatic renal cell carcinoma – πŸ“ BiomedicinesΒ  πŸ”’ Cited by: 4
πŸ“Œ Tumor-to-tumor metastasis of lung cancer to kidney cancer: a review of the literature and our experience – πŸ“ DiagnosticsΒ  πŸ”’ Cited by: 4
πŸ“Œ Second-line treatment of metastatic renal cell carcinoma in the era of predictive biomarkers – πŸ“ Diagnostics Β πŸ”’ Cited by: 3

Dr. Yihai Liu | Translational Medicine | Best Researcher Award

Published on by Biotechnology Scientist

Dr. Yihai Liu | Translational Medicine | Best Researcher Award

Dr. Yihai Liu | Nanjing Drum Tower Hospital | China

Dr. Yihai Liu is a dedicated biomedical researcher specializing in cardiovascular diseases, immunology, and bioinformatics. Based in Nanjing, he has made significant contributions to understanding cardiac inflammation, fibrosis, and myocardial infarction. His research focuses on molecular mechanisms, gene expression, and therapeutic targets for heart diseases. With numerous publications in high-impact journals, Dr. Liu is also an editor and reviewer for esteemed scientific journals. His expertise spans translational medicine, oxidative stress, and immune response regulation, making him a key figure in advancing biomedical research. Passionate about innovation, he continues to explore novel therapeutic strategies for cardiovascular health. 🧬❀️

Professional Profile:

Google Scholar

Suitability for the Best Researcher Award

Dr. Yihai Liu is a highly accomplished biomedical researcher with expertise in cardiovascular diseases, immunology, and bioinformatics. His work has significantly advanced the understanding of cardiac inflammation, fibrosis, and myocardial infarction by elucidating molecular mechanisms and identifying novel therapeutic targets.

Education & Experience πŸŽ“πŸ’Ό

  • πŸŽ“ B.Sc. – [University not specified]
  • πŸŽ“ Ph.D. – [University not specified]
  • 🏫 Lecturer (Year unspecified), Nanjing
  • πŸ”¬ Postdoctoral Researcher (Year unspecified), Nanjing
  • πŸ‘¨β€πŸ« Associate Professor/Professor (Year unspecified), Nanjing

Professional Development πŸ“šπŸ”

Dr. Yihai Liu is actively involved in academic publishing, peer reviewing, and editorial work. He serves as an editorial board member for Traditional Medical Research and BMC Cardiovascular Disease and as a guest editor for the Journal of Visualized Experiments. Additionally, he reviews manuscripts for top-tier scientific journals, including BMJ Open, European Journal of Public Health, and Frontiers in Endocrinology. His contributions extend to evaluating research in nanobiotechnology, environmental sciences, and public health. With a strong commitment to scientific integrity and innovation, Dr. Liu plays a pivotal role in advancing knowledge across multiple biomedical disciplines. πŸ…πŸ“–

Research FocusπŸ§ͺ🧬

Dr. Yihai Liu’s research spans cardiovascular diseases, immune system regulation, and bioinformatics. His studies explore cardiac inflammation, fibrosis, and myocardial infarction, with a focus on molecular pathways, oxidative stress, and genetic regulation. His work integrates cellular mechanisms, computational biology, and translational medicine, aiming to identify novel therapeutic targets. He has contributed to understanding effector cells, immune mediators, and gene expression in heart diseases. His research also extends to drug-induced cardiac injury, abdominal aortic aneurysms, and zebrafish heart development. Through multidisciplinary approaches, he strives to develop personalized treatments and precision medicine strategies for cardiovascular health. ❀️🩺

Awards & Honors πŸ†πŸŽ–οΈ

βœ… Editorial Board Member – Traditional Medical Research & BMC Cardiovascular Disease πŸ“š
βœ… Guest Editor – Journal of Visualized Experiments πŸ…
βœ… Reviewer for Prestigious Journals – BMJ Open, Journal of Nanobiotechnology, Frontiers in Endocrinology, British Journal of Nutrition, etc. ✍️
βœ… Published in High-Impact Journals – J Cell Physiol, J Int Med Res, Biochem Biophys Res Commun, etc. πŸ“–
βœ… Key Contributor to Bioinformatics Research – Identified therapeutic targets in hepatocellular carcinoma 🧬

Publication Top Notes:

πŸ“Œ miRNA-181a over-expression in mesenchymal stem cell-derived exosomes influenced inflammatory response after myocardial ischemia-reperfusion injury – Z Wei, S Qiao, J Zhao, Y Liu, Q Li, Z Wei, Q Dai, L Kang, B Xu Β πŸ”— Cited by: 194
🍎 Association between composite dietary antioxidant index and hypertension: insights from NHANES – M Wu, J Si, Y Liu, L Kang, B Xu Β πŸ“ˆ Cited by: 89
🦠 Neutrophil to lymphocyte ratio (NLR) as a prognostic marker for in-hospital mortality of patients with sepsis: A secondary analysis based on a single-center, retrospective study – J Ni, H Wang, Y Li, Y Shu, Y Liu Β βš•οΈ Cited by: 80
πŸ’Š Hyaluronic acid-coated polymeric micelles with hydrogen peroxide scavenging to encapsulate statins for alleviating atherosclerosis – D Mu, J Li, Y Qi, X Sun, Y Liu, S Shen, Y Li, B Xu, B Zhang Β πŸ”¬ Cited by: 46
❀️ Empagliflozin protects against atherosclerosis progression by modulating lipid profiles and sympathetic activity – Y Liu, J Xu, M Wu, B Xu, L Kang πŸ’‰ Cited by: 45

 

 

 

Prof. Dr. Xueqing Yang | Molecular Biology | Best Researcher Award

Published on by Biotechnology Scientist

Prof. Dr. Xueqing Yang | Molecular Biology | Best Researcher Award

Prof. Dr. Xueqing Yang | Shenyang Agricultural University | China

Dr. Xue-Qing Yang is a distinguished Professor of Entomology at the College of Plant Protection, Shenyang Agricultural University, China. With a deep passion for insect ecology and molecular biology, he has made significant contributions to insect ecological toxicology and molecular ecology. His research focuses on understanding insect physiology, genetics, and pest control strategies, particularly using advanced biotechnological tools like CRISPR/Cas9. Dr. Yang has published extensively in high-impact journals and has played a vital role in pest management and ecological conservation. His work continues to influence modern entomology, sustainable agriculture, and biocontrol innovations. πŸŒ±πŸ›

Professional Profile:

ORCID

SuitabilityΒ for Best Researcher Award

Dr. Xue-Qing Yang is a highly distinguished researcher in the field of entomology, specializing in insect ecological toxicology and molecular ecology. His extensive contributions to pest management, ecological conservation, and biotechnology-driven pest control strategies position him as a strong candidate for a Best Researcher Award. His interdisciplinary approach, integrating molecular biology, genetics, and ecology, has significantly advanced modern entomological research and sustainable agriculture.

Education & Experience πŸŽ“πŸ’Ό

  • πŸŽ“ B.Sc. (2004-2009) – Northwest A&F University, China
  • πŸŽ“ Ph.D. (2009-2014) – Northwest A&F University, China
  • πŸŽ“ Ph.D. (2014) – Northwest A&F University, China
  • 🏫 Lecturer (Sep. 2014 – Oct. 2017) – Shenyang Agricultural University, China
  • πŸ§‘β€πŸ”¬ Postdoctoral Researcher (Dec. 2016 – Sep. 2018) – Shenyang Agricultural University, China
  • πŸ… Associate Professor (Nov. 2017 – Oct. 2020) – Shenyang Agricultural University, China
  • πŸ‘¨β€πŸ« Professor (Nov. 2020 – Present) – Shenyang Agricultural University, China

Professional Development πŸ“–πŸ”

Dr. Yang has consistently advanced his professional expertise by integrating entomology, toxicology, and molecular biology into cutting-edge research. His postdoctoral work strengthened his expertise in insect molecular ecology, and he quickly progressed to a full professorship due to his impactful contributions. He actively collaborates with international researchers, mentoring young scientists in molecular entomology and pest management. With a strong presence in scientific publishing and academia, he has significantly influenced sustainable agriculture, integrated pest management (IPM), and insecticide resistance studies. His dedication to scientific innovation and ecological preservation positions him as a leader in modern insect science. 🧬🐞

Research Focus πŸ”¬πŸ¦Ÿ

Dr. Yang’s research primarily revolves around insect ecological toxicology and insect molecular ecology, with a strong emphasis on pest management and biocontrol strategies. His work involves genetic engineering, molecular mechanisms of insecticide resistance, and ecological adaptations of pests. Utilizing CRISPR/Cas9, he has pioneered gene-editing techniques to study insect reproduction and sterility mechanisms, crucial for developing sustainable pest control methods. Additionally, his studies explore semiochemical-based pest control, such as linalool fumigation to enhance mating competitiveness in insect populations. His research is at the forefront of biotechnological innovations in entomology and ecological conservation. πŸ§ͺ🌾

Awards & Honors πŸ†πŸŽ–οΈ

  • πŸ… Outstanding Young Scientist Award, Shenyang Agricultural University
  • πŸ“œ Top Research Contribution Award, College of Plant Protection
  • 🌟 Best Paper Award, Insect Biochemistry and Molecular Biology
  • πŸ₯‡ Excellence in Teaching & Mentorship, Entomology Department
  • πŸ”¬ Key Investigator Recognition, National Research Grants on Pest Management

Publication Top Notes:

  • “Stability, Inheritance, Cross-Resistance, and Fitness Cost of Resistance to Ξ»-Cyhalothrin in Cydia pomonella” – Journal of Agricultural and Food ChemistryΒ  🧬
  • Β “Loss-of-function in testis-specific serine/threonine protein kinase triggers male infertility in an invasive moth” – Communications Biology πŸ¦‹
  • Β “Establishing a fluorescence-based technique for ABC transporters functional analysis in metabolism of insecticides in a Lepidopteron” – Environmental Technology & InnovationπŸ”¬
  • Β “Tuta absoluta management in China: progress and prospects” – Entomologia GeneralisΒ  🌱
  • “Secondary metabolites in host pears defense against two fruit borers and cytochrome-P450-mediated counter-defense” – iScience  🍐

 

 

 

Prof. Dr. Yanchuan Li | Tumor Immunology | Best Researcher Award

Published on by Biotechnology Scientist

Prof. Dr. Yanchuan Li | Tumor Immunology | Best Researcher Award

Prof. Dr. Yanchuan Li | Nanjing Medical University | China

Dr. Yanchuan Li (李砚川), born in 1985 in Pingxiang, Jiangxi, is a distinguished cancer immunology researcher. He earned his Ph.D. in Biochemistry and Molecular Biology from Peking Union Medical College (Tsinghua University School of Medicine) in 2016 under the mentorship of Academician Linfang Wang and Prof. Shao-Cong Sun. Currently, he is a Professor and Ph.D. advisor at Nanjing Medical University, focusing on tumor and immune research. His expertise spans lymphocyte receptor signaling, CAR-NKT cell therapy, and molecular immunology. His groundbreaking research has been published in Cell Research, Blood, JEM, and Nature Communications. He also serves as a reviewer for top journals like Cellular & Molecular Immunology, Nucleic Acids Research, and Molecular Therapy. πŸŽ“πŸ”

Professional Profile:

Google Scholar

Suitability for Best Researcher Award

Dr. Yanchuan Li is a highly suitable candidate for a Best Researcher Award due to his exceptional contributions to cancer immunology and molecular immunology. Dr. Li’s expertise in lymphocyte receptor signaling, CAR-NKT cell therapy, and tumor immunology has significantly advanced the understanding of immune regulation in cancer. His research impacts both fundamental immunological mechanisms and translational applications, making him a distinguished figure in the field.

Education & Experience πŸ“šπŸ‘¨β€πŸ”¬

  • 2012-2016 πŸŽ“ Ph.D. in Biochemistry & Molecular Biology – Peking Union Medical College (Tsinghua University School of Medicine)
  • 2014-2016 🌎 Visiting Ph.D. Scholar – MD Anderson Cancer Center, USA (CSC Scholarship)
  • 2016-2021 πŸ§ͺ Postdoctoral Research Fellow – MD Anderson Cancer Center, USA
  • 2021-2022 πŸ₯ Research Scientist – MD Anderson Cancer Center, USA
  • 2022-2023 πŸ”¬ Research Associate – Baylor College of Medicine, USA
  • 2023-Present πŸŽ“ Professor & Ph.D. Supervisor – Nanjing Medical University

Professional Development πŸ”¬πŸ“ˆ

Dr. Li’s research bridges fundamental tumor immunology and translational medicine, employing cell culture, gene manipulation, proteomics, and multi-omics approaches. His work utilizes CRISPR/Cas9 screening, single-cell analysis, and knockout mouse models to uncover key immune signaling mechanisms. His significant contributions to B cell function, CAR-NKT therapy, and immune regulation in major diseases are paving the way for innovative cancer treatments. He has played a key role in developing CAR-NKT cell therapies, including a clinical trial for relapsed neuroblastoma. His dedication to scientific excellence and interdisciplinary collaboration is shaping the future of cancer immunotherapy. πŸ₯πŸ§¬πŸ’‘

Research Focus πŸ”πŸ¦ 

Dr. Li’s research covers tumor immunology and translational medicine, with key interests in:
1️⃣ B Cell Function & Autoimmunity – Exploring B cell activation in diseases like SLE & B cell leukemia. πŸ”¬πŸ¦ 
2️⃣ CAR-NKT Cell Therapy – Engineering NKT cells for safer and more effective cancer immunotherapy. πŸŽ―πŸ’‰
3️⃣ Molecular Mechanisms of Major Diseases – Utilizing multi-omics & disease models to investigate cancer progression, autoimmune disorders, and drug response. πŸ§ͺπŸ“Š
4️⃣ Advanced Immuno-Analytical Techniques – Developing single-cell spatial transcriptomics, CRISPR-based screens, and novel proteomics to revolutionize cancer research. πŸ”πŸ”¬

Awards & Honors πŸ†πŸŽ–οΈ

  • πŸ… Outstanding Ph.D. Graduate – Peking Union Medical College, 2016
  • πŸ… Outstanding Ph.D. Graduate – Beijing Municipality, 2016
  • ⭐ Annual Excellence Award – Nanjing Medical University, 2023
  • πŸ’° West Taihu Cell Therapy Foundation Grant – 500,000 CNY

Publication Top Notes:Β 

πŸ“’Β Proinflammatory TLR signalling is regulated by a TRAF2-dependent proteolysis mechanism in macrophages – Cited by 97 πŸ”¬
🧬Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results – Cited by 87 πŸ₯
🦠 TBKBP1 and TBK1 form a growth factor signalling axis mediating immunosuppression and tumourigenesis – Cited by 78 🧫
πŸ›‘Cell intrinsic role of NF-ΞΊB-inducing kinase in regulating T cell-mediated immune and autoimmune responses – Cited by 67 πŸ‹οΈ
🧩 Β Preventing abnormal NF-ΞΊB activation and autoimmunity by Otub1-mediated p100 stabilization – Cited by 44 πŸ—
🦠 NIK signaling axis regulates dendritic cell function in intestinal immunity and homeostasis – Cited by 44 🦠
πŸ”₯ Peli1 facilitates NLRP3 inflammasome activation by mediating ASC ubiquitination – Cited by 43 πŸš€
🧠 Microglia promote autoimmune inflammation via the noncanonical NF-ΞΊB pathway – Cited by 42 🧠
🌿 Β Protective effect of melatonin on cigarette smoke‐induced restenosis in rat carotid arteries after balloon injury – Cited by 40 πŸŒ™
🦠 Intestinal epithelial TBK1 prevents differentiation of T-helper 17 cells and tumorigenesis in mice – Cited by 30 πŸ₯

 

 

 

Prof. Dr. Alexa Klettner | Macular Degeneration | Best Researcher Award

Published on by Biotechnology Scientist

Prof. Dr. Alexa Klettner | Macular Degeneration | Best Researcher Award

Prof. Dr. Alexa Klettner | UKSH Kiel | Germany

πŸ‘©β€πŸ”¬ Alexa Karina Klettner is a University Professor of Experimental Retinology at Kiel University in Germany, specializing in age-related macular degeneration. With a Ph.D. in Natural Sciences and a Habilitation in Experimental Ophthalmology, she investigates cellular pathological pathways and innovative therapeutics. Her work extends to developing advanced research models for retinal diseases. An advocate for international collaboration, Alexa has partnered with institutions worldwide and published over 95 PubMed articles. Her pioneering research on retinal health and ocular biomarkers significantly impacts the field of ophthalmology.

Professional Profile:

ORCID

SCOPUS

Suitability for Best Researcher Award

Alexa Karina Klettner is a distinguished University Professor of Experimental Retinology at Kiel University, Germany, specializing in age-related macular degeneration (AMD). Her academic journey is marked by a Ph.D. in Natural Sciences and a Habilitation in Experimental Ophthalmology, reflecting her deep expertise and commitment to retinal research. Her focus on cellular pathological pathways and innovative therapeutics addresses critical challenges in AMD, contributing significantly to the understanding and potential treatment of this vision-threatening condition.

Education and Experience:

πŸŽ“ Diploma in Biology – Equivalent to Master of Science
πŸŽ“ Ph.D. in Natural Sciences – Specialized in Experimental Ophthalmology
πŸŽ“ Habilitation – Advanced German academic qualification exceeding Ph.D.
πŸ‘©β€πŸ« University Professor – Experimental Retinology, Kiel University, Germany
🌍 Adjunct Professor – University of Cairo, Egypt
πŸ”¬ Researcher – Focused on macular degeneration, therapeutic development, and advanced research models

Professional Development:

πŸ”¬ Alexa Karina Klettner has significantly contributed to understanding retinal cell pathology and innovative therapeutic approaches, particularly in age-related macular degeneration. Her work on the effects of VEGF inhibitors and inflammatory RPE activation has influenced modern ophthalmological treatments. Additionally, she pioneered the development of RPE/choroid organ cultures and porcine retinal cell cultures, advancing research models. Through international collaborations and participation in multinational projects like FucoSan and AlgaeProBanos, Alexa has driven global research initiatives. Her commitment to blue bioeconomy and alternatives to animal experimentation demonstrates her forward-thinking approach in experimental retinology.

Research Focus:

πŸ‘οΈ Age-Related Macular Degeneration (AMD) – Investigating cellular pathological pathways and developing new therapeutics.
πŸ§ͺ Inflammatory Activation – Exploring inflammatory RPE activation and its interaction with innate immune cells.
πŸ’‰ Therapeutic Innovation – Researching VEGF inhibitors’ (side-)effects and introducing novel treatments for subretinal hemorrhage.
πŸ”¬ Advanced Research Models – Creating RPE/choroid organ cultures and porcine retinal cell cultures for enhanced disease modeling.
🌊 Blue Bioeconomy – Integrating marine-derived compounds like fucoidan as potential retinal disease therapeutics.
🧠 Neuroscience & Biomarkers – Discovering ocular biomarkers linked to neurodegenerative diseases, including Parkinson’s.

Awards and Honors:

πŸ† Leonard-Klein Award – For developing new treatment procedures for subretinal hemorrhage.
🌍 International Collaborations – Leading multinational research projects and bilateral cooperations.
πŸ“Š H-index: 28 – Reflecting impactful contributions to ophthalmology research.
πŸ“š Books Published – Authored 4 books contributing to the field of retinology and experimental ophthalmology.
🌐 Editorial Appointments – Served on editorial boards, influencing ophthalmic research publication standards.

Publication Top Notes:

  • πŸ“˜ Effects of Fucoidans on Activated Retinal Microglia – 2024 – πŸ“Š
  • πŸ“˜ A systematic review of the cell death mechanisms in retinal pigment epithelium cells and photoreceptors after subretinal hemorrhage – Implications for treatment options – 2023 – πŸ“Š 2 citations
  • πŸ“˜ Establishment of specific age-related macular degeneration relevant gene expression panels using porcine retinal pigment epithelium for assessing fucoidan bioactivity – 2023 – πŸ“Š 4 citations
  • πŸ“˜ Comparison of Fucoidans from Saccharina latissima Regarding Age-Related Macular Degeneration Relevant Pathomechanisms in Retinal Pigment Epithelium – 2023 – πŸ“Š 6 citations
  • πŸ“˜ Anti-inflammatory properties of antiangiogenic fucoidan in retinal pigment epithelium cells – 2023 – πŸ“Š 3 citations
  • πŸ“˜ Interaction of High-Molecular Weight Fucoidan from Laminaria hyperborea with Natural Functions of the Retinal Pigment Epithelium – 2023 – πŸ“Š 8 citations
  • πŸ“˜ Properties of Cephalopod Skin Ommochromes to Inhibit Free Radicals, and the Maillard Reaction and Retino-Protective Mechanisms in Cellular Models Concerning Oxidative Stress, Angiogenesis, and Inflammation – 2022 – πŸ“Š 7 citations

 

 

 

Assist. Prof. Dr. Keyang Xu | oncology | Best Researcher Award

Published on by Biotechnology Scientist

Assist. Prof. Dr. Keyang Xu | oncology | Best Researcher Award

Assist. Prof. Dr. Keyang Xu | Macau University of Science and Technology | China

πŸŽ“ Dr. Keyang Xu is an Assistant Professor at the Faculty of Chinese Medicine, Macau University of Science and Technology. His research explores the intersections of oncology and metabolism, focusing on exosomes, proteomics, noncoding RNA, and natural therapies. With extensive experience from prestigious institutions like Hong Kong Baptist University and the University of Sydney, Dr. Xu is dedicated to advancing cancer research and translational medicine. He actively contributes as an editor for Frontiers in Oncology and the Journal of Taibah University for Science, driving scientific innovation in his field.

Professional Profile:

ORCID

Suitability for Best Researcher Award

Dr. Keyang Xu is an exceptional candidate for the Best Researcher Award, given his pioneering contributions to oncology and metabolism. As an Assistant Professor at the Faculty of Chinese Medicine, Macau University of Science and Technology, Dr. Xu explores cutting-edge areas including exosomes, proteomics, noncoding RNA, and natural therapies, which are at the forefront of cancer research and translational medicine. His interdisciplinary approach bridges traditional Chinese medicine with modern biomedical science, paving the way for innovative cancer therapies.

Education & Experience:

  • πŸŽ“ Ph.D. in Chinese Medicine – Hong Kong Baptist University (2021-2024)
  • πŸŽ“ Visitor Scholar – Storr Liver Center, University of Sydney (2024)
  • πŸŽ“ Master’s Degree – Chinese & Western Clinical Medicine, Zhejiang Chinese Medical University (2016-2019)
  • πŸŽ“ Medicine Degree – Chengdu University of Traditional Chinese Medicine (2011-2016)
  • πŸ§‘β€πŸ« Assistant Professor – Macau University of Science and Technology (2025-Present)
  • πŸ”¬ Research Assistant – Hong Kong Baptist University (2020-2024)
  • 🩺 Physician – Lvkang Geriatric Rehabilitation Hospital, Hangzhou (2019-2020)
  • 🩺 Physician – Xiwenbeiyuan Clinic, Hangzhou (2018-2019)

Professional Development:

🌏 Global Collaborations – Dr. Xu has collaborated internationally, including with renowned experts at the Storr Liver Center in Sydney.
πŸ“š Editorial Roles – He actively contributes to scientific literature as an editor for Frontiers in Oncology and the Journal of Taibah University for Science.
πŸŽ“ Mentorship & Teaching – As an Assistant Professor, he guides future researchers and medical professionals.
πŸ”¬ Innovative Research – His research delves into the roles of exosomes, proteomics, noncoding RNA, and natural therapies in oncology and metabolism.
🀝 Professional Memberships – Active in the Good Practice in Traditional Chinese Medicine Research Association and Student Networks on EVs, fostering a collaborative scientific community.

Research Focus:

🧬 Oncology & Metabolism – Investigating the mechanisms linking cancer and metabolic disorders.
πŸ“¦ Exosomes – Exploring the role of adipose tissue-derived exosomes in cancer metastasis and metabolic regulation.
πŸ§ͺ Proteomics – Utilizing omics approaches to understand protein profiles influenced by obesity and metabolic changes.
🧬 Noncoding RNA – Investigating lncRNAs’ role in cancer progression and recurrence, particularly in HBV-related hepatocellular carcinoma.
🌿 Natural Therapy – Examining the therapeutic effects of natural compounds like Resveratrol on metabolic diseases and cancer.

Awards & Honors:

  • πŸ… Research Grant – High-fat diet-enhanced colorectal cancer metastasis project (RC-FNRA-IG/20-21/SCM/01)
  • πŸ… Research Grant – Effects of obesity on exosomal protein profiles (#2021Szvup131)
  • πŸ… Research Grant – Molecular mechanism of LncBRM in HBV-related hepatocellular carcinoma (LSY19H030002)
  • πŸ… Research Grant – Treating hyperuricemia-related NAFLD with Resveratrol (2014ZA090)
  • πŸ… Research Grant – Clinical value of CHI3L1 in chronic hepatitis B (2019KY532)

Publication Top Notes:

  • “An Integration of RNA Sequencing and Network Pharmacology Approaches Predicts the Molecular Mechanisms of the Huo-Xue-Shen Formula in the Treatment of Liver Fibrosis”Β  – πŸ§¬πŸ“Š
  • “Exosomes in Skin Flap Survival: Unlocking Their Role in Angiogenesis and Tissue Regeneration”Β  – 🧫🩺
  • “Shared Genetic Links Between Nonalcoholic Fatty Liver Disease and Coronary Artery Disease” – 🧬❀️
  • “Exploring Tumor Heterogeneity in Colorectal Liver Metastases by Imaging: Unsupervised Machine Learning of Preoperative CT Radiomics Features for Prognostic Stratification”Β  – πŸ§ πŸ€–
  • “Elevated Extracellular Matrix Protein 1 in Circulating Extracellular Vesicles Supports Breast Cancer Progression Under Obesity Conditions” – πŸ§¬βš–οΈ
  • “Untimely Surgery for Stent-Fracture-Related Death After Transjugular Intrahepatic Portosystemic Shunt: A Case Report” – πŸ©ΊπŸ“„
  • “Brevilin A is a Potent Anti-Metastatic CRC Agent That Targets the VEGF-IL6-STAT3 Axis in the HSCs-CRC Interplay”Β  – πŸ§¬πŸ›‘οΈ